Proteomics technology developer Quantum-Si reported a 5 percent year-over-year revenue decline in Q2 2025, attributed primarily to funding constraints from the NIH that slowed capital sales processes. The Connecticut-based firm noted initiatives to diversify instrument acquisition models and sustain technological progress, including upcoming launches of sequencing kits and a prototype instrument demonstration planned by year-end. Despite headwinds, management remains optimistic about product development momentum and user base growth.